PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma

References

• Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M. Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal. 2020;18(1):127.
   PubMed Web of Science ®Google Scholar
• Mossanen M. The epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2021;35(3):445–455.
   PubMed Web of Science ®Google Scholar
• Barani M, Hosseinikhah SM, Rahdar A, et al. Nanotechnology in bladder cancer: diagnosis and treatment. Cancers (Basel). 2021;13(9):2214.
   PubMed Web of Science ®Google Scholar
• Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15.
   PubMedGoogle Scholar
• Batista R, Vinagre N, Meireles S, et al. Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review. Diagnostics (Basel). 2020;10(1):39.
   PubMedGoogle Scholar
• Sciarra A, Di Lascio G, Del Giudice F, et al. Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review. Curr Urol. 2021;15(1):22–32.
   PubMedGoogle Scholar
• Georgantzoglou N, Pergaris A, Masaoutis C, Theocharis S. Extracellular vesicles as biomarkers carriers in bladder cancer: diagnosis, surveillance, and treatment. Int J Mol Sci. 2021;22(5):2744.
   PubMed Web of Science ®Google Scholar
• Li Santi A, Napolitano F, Montuori N, Ragno P. The urokinase receptor: a multifunctional receptor in cancer cell biology. therapeutic implications. Int J Mol Sci. 2021;22(8):4111.
   PubMed Web of Science ®Google Scholar
• Napolitano F, Montuori N. The role of the plasminogen activation system in angioedema: novel insights on the pathogenesis. J Clin Med. 2021;10(3):518.
   PubMed Web of Science ®Google Scholar
• Dowsett J, Ferkingstad E, Rasmussen LJH, et al. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor. Commun Biol. 2021;4(1):655.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382(5):416–426.
   PubMed Web of Science ®Google Scholar
• Lino N, Fiore L, Rapacioli M, et al. uPA-uPAR molecular complex is involved in cell signaling during neuronal migration and neuritogenesis. Dev Dyn. 2014;243(5):676–689.
   PubMed Web of Science ®Google Scholar
• Biagioni A, Chillà A, Del Rosso M, et al. CRISPR/Cas9 uPAR gene knockout results in tumor growth inhibition, EGFR downregulation and induction of stemness markers in melanoma and colon carcinoma cell lines. Front Oncol. 2021;11:663225.
   PubMed Web of Science ®Google Scholar
• Yang QX, Zhong S, He L, et al. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett. 2019;452:90–102.
   PubMed Web of Science ®Google Scholar
• Hu X, Mandika C, He L, et al. Construction of urokinase-type plasminogen activator receptor-targeted heterostructures for efficient photothermal chemotherapy against cervical cancer to achieve simultaneous anticancer and antiangiogenesis. ACS Appl Mater Interfaces. 2019;11(43):39688–39705.
   PubMed Web of Science ®Google Scholar
• Rysenkova KD, Klimovich PS, Shmakova AA, et al. Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells. Cell Signal. 2020;75:109741.
   PubMed Web of Science ®Google Scholar
• Semina EV, Rubina KA, Shmakova AA, et al. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma. J Cell Physiol. 2020;235(9):6268–6286.
   PubMed Web of Science ®Google Scholar
• Biagioni A, Laurenzana A, Menicacci B, et al. uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and Upar overexpression and rise of ERK1,2 signaling in endothelial cells. Cell Mol Life Sci. 2021;78(6):3057–3072.
   PubMed Web of Science ®Google Scholar
• Bharadwaj AG, Holloway RW, Miller VA, Waisman DM. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers (Basel). 2021;13(8):1838.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei H, Qian D, et al. Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma. Ann Transl Med. 2020;8(18):1152.
   PubMed Web of Science ®Google Scholar
• Liu M, Zheng Q, Chen S, Liu J, Li S. FUT7 promotes the epithelial-mesenchymal transition and immune infiltration in bladder urothelial carcinoma. J Inflamm Res. 2021;14:1069–1084.
   PubMed Web of Science ®Google Scholar
• Eich ML, Rodriguez Pena MDC, Chandrashekar DS, et al. Expression and role of methylenetetrahydrofolate dehydrogenase 1 like (MTHFD1L) in bladder cancer. Transl Oncol. 2019;12(11):1416–1424.
   PubMed Web of Science ®Google Scholar
• Sidaway P. Bladder cancer: uPAR expression indicates worse prognosis of urothelial carcinoma. Nat Rev Urol. 2015;12(3):120.
   Google Scholar
• Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69(1):3–14.
   PubMed Web of Science ®Google Scholar
• Nie Z, Chen M, Wen X, et al. Endoplasmic reticulum stress and tumor microenvironment in bladder cancer: the missing link. Front Cell Dev Biol. 2021;9:683940.
   PubMed Web of Science ®Google Scholar
• Annels NE, Simpson GR, Pandha H. Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response. Front Oncol. 2020;10:175.
   PubMed Web of Science ®Google Scholar
• Daza J, Charap A, Wiklund PN, Sfakianos JP. Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer. Eur Urol Focus. 2020;6(4):650–652.
   PubMedGoogle Scholar
• Lv Y, Jin P, Chen Z, Zhang P. Characterization of hazard infiltrating immune cells and relative risk genes in bladder urothelial carcinoma. Am J Transl Res. 2020;12(11):7510–7527.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yu M, Guo L, et al. Tumor derived SIGLEC family genes may play roles in tumor genesis, progression, and immune microenvironment regulation. Front Oncol. 2020;10:586820.
   PubMed Web of Science ®Google Scholar
• Peng Q, Liu Y, Kong X, et al. The novel methylation biomarker SCARA5 sensitizes cancer cells to DNA damage chemotherapy drugs in NSCLC. Front Oncol. 2021;11:666589.
   PubMed Web of Science ®Google Scholar
• Flausino CS, Daniel FI, Modolo F. DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs. Crit Rev Oncol Hematol. 2021;164:103399.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yin J, Luo L, et al. Integrative analysis of DNA methylation and transcriptome identifies a predictive epigenetic signature associated with immune infiltration in gliomas. Front Cell Dev Biol. 2021;9:670854.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang Z, Zheng Q, Li J. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma. Gene. 2021;790:145689.
   PubMed Web of Science ®Google Scholar
• Zhen L, Ning G, Wu L, et al. Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma. Biosci Rep. 2020;40(10):BSR20192593.
   PubMedGoogle Scholar